Últimas noticias sobre Champions Oncology (NASDAQ:CSBR) Bolsa

Champions Oncology

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ADBE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este jueves: KR, OXM, SIG, CSBR y ADBE.

5 acciones en el foco este jueves: KR, OXM, SIG, CSBR y ADBE

Champions Oncology Inc

Contracts

Press Releases

Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024

Champions Oncology Reports Quarterly Revenue of $14.0 Million

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024

Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

Champions Oncology Announces Agreement with Weill Cornell Medicine

Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting

Akoya Biosciences

Applied DNA Sciences, Inc. - Common Stock

Applied DNA Sciences

Atlantic International Corp. - Common Stock

Atlantic International

Bionano Genomics

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals

Codexis

CryoPort

Harvard Bioscience

Standard BioTools

Lifecore Biomedical

MaxCyte

Nautilus Biotechnology, Inc. - Common Stock

Nautilus Biotechnology

Inotiv

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Rapid Micro Biosystems, Inc. - Class A Common Stock

Rapid Micro Biosystems

Seer

Alpha Teknova

Craig-Hallum

Roth MKM

Comments

Champions Oncology

Noticias

Últimas noticias sobre Champions Oncology (NASDAQ:CSBR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL